Hormonosubstitution postmenopausique et risque de cancer mammaire: une mise a jour

Estrogen Replacement Therapy/adverse effects; Breast Neoplasms/etiology; Hormone replacement therapy; menopause; Breast cancer; Risk; Research Design; Postmenopause; Humans; Female

Abstract :

[en] Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The observed results present with weak variations from baseline and major heterogeneity. Some studies highlight a slightly increased relative risk of breast cancer. A reanalysis of 51 studies demonstrates a relative risk of 1.35 for developing breast cancer during hormone substitution, with a 2.3% increased risk per year of use. Recently, the results of the WHI study have shown a slight increase of some risks of disease, including breast cancer (relative risk, 1.26). These results have induced the interruption of one of the 3 arms of the study (that of the patients treated with an estrogen-progestin combination), and have provoked a new discussion about the benefits and risks associated with hormone substitution. These facts have been largely related and commented in the general press. In this article, we review the important studies concerning this topic.

Disciplines :

Radiology, nuclear medicine & imaging
Reproductive medicine (gynecology, andrology, obstetrics)

Author, co-author :

van den Brule, F.

Lifrange, Eric ; Centre Hospitalier Universitaire de Liège - CHU > Sénologie

Pintiaux, Axelle ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique

Gaspard, Ulysse ; Centre Hospitalier Universitaire de Liège - CHU

Language :

French

Title :

Hormonosubstitution postmenopausique et risque de cancer mammaire: une mise a jour

Alternative titles :

[en] Postmenopausal Hormone Replacement Therapy and Breast Cancer Risk: An Update

Publication date :

April 2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

254-60

Peer reviewed :

Peer reviewed

Available on ORBi :

since 21 March 2010

Statistics

Number of views

133 (4 by ULiège)

Number of downloads

55 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Rossouw JE, Anderson GL, Prentice RL, et al. - Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-33.
Thomas DB. - Do hormones cause breast cancer ? Cancer, 1984, 53, 595-604.
King RJ. - A discussion of the roles of oestrogen and progestin in human mammary carcinogenesis. J Steroid Biochem Mol Biol, 1991, 39, 811-8.
Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. - A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst, 1995, 87, 190-7.
Berrino F, Muti P, Micheli A, et al. - Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst, 1996, 88, 291-6.
Cauley JA, Lucas FL, Kuller LH, et al. - Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA, 1996, 276, 1404-8.
Zhang Y, Kiel DP, Kreger BE, et al. - Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med, 1997, 336, 611-7.
Folsom AR, Mink PJ, Sellers TA, et al. - Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health, 1995, 85, 1128-32.
Gapstur SM, Morrow M, Sellers TA. - Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA, 1999, 281, 2091-7.
Persson I, Weiderpass E, Bergkvist L, et al. - Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control, 1999, 10, 253-60.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. - Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst, 2000, 92, 328-32.
Schairer C, Lubin J, Troisi R, Sturgeon S, et al. - Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA, 2000, 283, 485-91.
Olsson H, Bladstrom A, Ingvar C, Moller TR. - A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer, 2001, 85, 67-47.
Weiss LK, Burkman RT, Cushing-Haugen KL, et al. - Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol, 2002, 100, 1148-58.
Dupont WD, Page DL, Parl FF, et al. - Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer, 1999, 85, 1277-83.
Byrne C, Connolly JL, Colditz GA, Schnitt SJ. - Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer, 2000, 89, 2046-52.
Sellers TA, Mink PJ, Cerhan JR, et al. - The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med, 1997, 127, 973-80.
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 2001, 358, 1389-99.
Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol, 1995, 142, 788-95.
Colditz GA, Stampfer MJ, Willett WC, et al. - Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA, 1990, 264, 2648-53.
Colditz GA, Stampfer MJ, Willett WC, et al. - Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control, 1992, 3, 433-9.
Colditz GA, Hankinson SE, Hunter DJ, et al. - The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med, 1995, 332, 1589-93.
Colditz GA, Rosner B. - Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol, 2000, 152, 950-64.
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 1995, 273, 199-208.
Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA, 1996, 276, 1389-96.
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 1996, 275, 370-5.
Espeland MA, Hogan PE, Fineberg SE, et al. - Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care, 1998, 21, 1589-95.
Petitti DB. - Meta-analysis, detection analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Oxford University Press, New York, 1994.
Bush TL, Whiteman M, Flaws JA. - Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol, 2001, 98, 498-508.
Wren BG. - Megatrials of hormonal replacement therapy. Drugs Aging, 1998, 12, 343-8.
Hormone replacement therapy. Clinical Synthesis Panel on HRT. Lancet, 1999, 354, 152-5.
Speroff L. - Postmenopausal hormone therapy and the risk of breast cancer. Maturitas, 1999, 32, 123-9.
Speroff L. - Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports. Climacteric, 2000, 3, 3-12.
Solomon CG, Dluhy RG. - Rethinking postmenopausal hormone therapy. N Engl J Med, 2003, 348, 579-80.
Collaborative Group on Hormonal Factors in Breast Cancer. - Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet, 1997, 350, 1047-59.
Willis DB, Calle EE, Miracle-McMahill HL, Heath CW, Jr. - Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control, 1996, 7, 449-57.
Grodstein F, Stampfer MJ, Colditz GA, et al. - Postmenopausal hormone therapy and mortality. N Engl J Med, 1997, 336, 1769-75.
Henderson BE, Paganini-Hill A, Ross RK. - Decreased mortality in users of estrogen replacement therapy. Arch Intern Med, 1991, 151, 75-8.
Nanda K, Bastian LA, Schulz K. - Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol, 2002, 186, 325-34.
Hunt K, Vessey M, McPherson K. - Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol, 1990, 97, 1080-6.
Strickland DM, Gambrell RD Jr., Butzin CA, Strickland K. - The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol, 1992, 80, 400-4.
Bonnier P, Romain S, Giacalone PL, et al. - Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol, 1995, 85, 11-7.
Li CI, Weiss NS, Stanford JL, Daling JR. - Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer, 2000, 88, 2570-7.
Manjer J, Malina J, Berglund G, et al. - Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer, 2001, 92, 919-22.
Chen CL, Weiss NS, Newcomb P, et al. - Hormone replacement therapy in relation to breast cancer. JAMA, 2002, 287, 734-41.
Daling JR, Malone KE, Doody DR, et al. - Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer, 2002, 95, 2455-64.
Sacchini V, Zurrida S, Andreoni G, et al. - Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol, 2002, 9, 266-71.
Magnusson C, Holmberg L, Norden T, et al. - Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat, 1996, 38, 325-34.
LaCroix AZ, Burke W. - Breast cancer and hormone replacement therapy. Lancet, 1997, 350, 1042-3.
Ettinger B, Guesenberry C, Schroeder DA, Friedman G. - Long-term postmenopausal estrogen therapy may be associated with increased risk of breast cancer. Menopause, 1997, 4, 125-129.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 1998, 90, 1371-88.
Cummings SR, Eckert S, Krueger KA, et al. - The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, 281, 2189-97.
Wertheimer MD, Costanza ME, Dodson TF, et al. Increasing the effort toward breast cancer detection. JAMA, 1986, 255, 1311-5.
Gavaler JS, Van Thiel DH. - The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature. Alcohol Clin Exp Res, 1992, 16, 87-92.
Ginsburg ES, Mello NK, Mendelson JH, et al. - Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA, 1996, 276, 1747-51.
Ginsburg ES. - Estrogen, alcohol and breast cancer risk. J Steroid Biochem Mol Biol, 1999, 69, 299-306.
Yang CP, Daling JR, Band PR, et al. - Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control, 1992, 3, 475-9.
Schairer C, Byrne C, Keyl PM, et al. - Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control, 1994, 5, 491-500.
Risch HA, Howe GR. - Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol, 1994, 139, 670-83.
Stanford JL, Weiss NS, Voigt LF, et al. - Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA, 1995, 274, 137-42.
Magnusson C, Persson I, Adami HO. - More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst, 2000, 92, 1183-4.
Ferguson DJ, Anderson TJ. - Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer, 1981, 44, 177-81.
Vogel PM, Georgiade NG, Fetter BF, et al. - The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol, 1981, 104, 23-34.
Longacre TA, Bartow SA. - A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol, 1986, 10, 382-93.
Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol, 1988, 130, 193-204.
Potten CS, Watson RJ, Williams GT, et al. - The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer, 1988, 58, 163-70.
Desreux J, van den Brûle F, Noël A, et al. - The effects of progesterone on breast tissue. J für Menopause, 2001, 8, 14-18.
van den Brûle F, Desreux J, Béliard A, et al. - Influence du régime d'administration continu ou discontinu d'acétate de nomégestrol sur l'apoptose des cellules mammaires. Reprod Hum Horm, 2001, 14, 243-248.
Phillips KA, Glendon G, Knight JA. - Putting the risk of breast cancer in perspective. N Engl J Med, 1999, 340, 141-4.
Balfour JA, Goa KL. - Raloxifene. Drugs Aging, 1998, 12, 335-41; discussion 342.
van den Brûle FA, Kalbus M-F, Gaspard UJ. - Le raloxifène: un modulateur sélectif du récepteur aux oestrogènes. J Gyn Obstet Biol Reprod, 1999, 28, 788-799.
Chlebowski RT. - Reducing the risk of breast cancer. N Engl J Med, 2000, 343, 191-8.
Riggs BL et Hartmann LC. - Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med, 2003, 348, 618-29.
Ettinger B, Black DM, Mitlak BH, et al. - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282, 637-45.
Lippman ME, Krueger KA, Eckert S, et al. - Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol, 2001, 19, 3111-6.
Cummings SR, Duong T, Kenyon E, et al. - Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA, 2002, 287, 216-20.